Area of research
Molecular Biology · Pathology and Forensic Medicine
Research interest
Research interests include Advanced biosensing and bioanalysis techniques, Lymphoma Diagnosis and Treatment, Immune cells in cancer, and Chronic Lymphocytic Leukemia Research.
Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T‐cell and natural killer‐cell neoplasms: A phase 2, multicenter, open‐label, single‐arm trial
61 | A PIVOTAL STUDY OF SHR2554, AN ORAL INHIBITOR AGAINST ENHANCER OF ZESTE HOMOLOG 2 (EZH2), IN RELAPSED OR REFRACTORY (R/R) PERIPHERAL T‐CELL LYMPHOMA (PTCL)
Self-‘cycling, boosting and propelling’ multi-functional nanoplatforms for improving tumor starvation therapy
366 | EVOLVING TREATMENT LANDSCAPE AND OUTCOMES IN ELDERLY HODGKIN LYMPHOMA: A 15‐YEAR MULTICENTER RETROSPECTIVE ANALYSIS FROM CHINA HIGHLIGHTING THE IMPACT OF NOVEL THERAPIES
Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors
Safety and Efficacy of Rocbrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma
Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open‐label study
Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
PI3Kδ Inhibitor Linperlisib As a ≥ 3-Line Treatment for Relapsed or Refractory Follicular Lymphoma: A Subgroup Analysis of a Phase II, Single-Arm, Open-Label Trial
P1099: A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF PARSACLISIB, A PI3KΔ INHIBITOR, IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA IN CHINA: UPDATED RESULTS FROM THE STUDY
Synthesis of microcapsules containing a formaldehyde scavenger for the sustainable control of hazardous chemical release from particleboard
Substrate promiscuities of a bacterial galactokinase and a glucose-1-phosphate uridyltransferase enable xylose salvaging
A phase II, multicenter, single-arm study of parsaclisib, a PI3Kδ inhibitor, in relapsed or refractory follicular lymphoma in China: Updated data from the study.
Sintilimab Plus Bevacizumab Biosimilar IBI305, and Chemotherapy for Patients with <i>EGFR</i>-Mutant Nonsquamous NSCLC Who Progressed on EGFR-TKI Therapy (ORIENT-31): Interim Results from a Randomized, Double-Blind, Phase 3 Study
The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Orelabrutinib in Chinese Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Updated Results of a Multicenter, Phase I/IIa Trial
A Preliminary Analysis of Chidamide Combined with R-GemOx (rituximab, gemcitabine and oxaliplatin) As Salvage Treatment for Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Study
Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer
Sintilimab for relapsed/refractory classical Hodgkin’s lymphoma: Extended follow-up on the multicenter, single-arm phase II ORIENT-1 study.
Sintilimab (IBI308) in relapsed/refractory classical Hodgkin lymphoma: A multicenter, single-arm phase 2 trial in China (ORIENT-1 study).
CD133 and MYCN Amplification Induce Chemo-Resistance and Reduce Average Survival Time in Pediatric Neuroblastoma